23 February 2021 - The drug at the centre of an inquest into six epilepsy deaths was made at a plant in India that was investigated for significant quality control issues in 2017.

The generic drug company Mylan uses a manufacturing facility in Nashik, in the west Indian state of Maharashtra, to manufacture and test Logem, a generic form of the anti-epileptic drug lamotrigine, sold in New Zealand.

Read Radio New Zealand article